( NASDAQ-NMS:VNDA )

News from Vanda Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 23, 2018, 08:00 ET HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from the JET Study (VP-VEC-162-2102), a 3-night transatlantic travel...


May 07, 2018, 09:00 ET Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Deutsche Bank 43rd Annual...


May 02, 2018, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31,...


Apr 18, 2018, 16:30 ET Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2018 on Wednesday, May 2, 2018,...


Apr 13, 2018, 12:00 ET Vanda Wins Appeal Case on Fanapt®

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District...


Apr 09, 2018, 16:01 ET Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis

Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced participation at the 2018 Georg Rajka International Symposium of Atopic...


Mar 15, 2018, 19:46 ET Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the sale of 5,500,000 shares of its common stock in an underwritten public...


Mar 14, 2018, 16:01 ET Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten...


Mar 06, 2018, 16:30 ET Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in March...


Mar 05, 2018, 07:00 ET HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ®, a circadian regulator, demonstrated significant and clinically...


Feb 14, 2018, 16:01 ET Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...


Jan 30, 2018, 16:30 ET Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter and full year 2017 on Wednesday,...


Jan 07, 2018, 09:00 ET Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies...


Nov 13, 2017, 09:00 ET Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in...


Nov 10, 2017, 16:05 ET Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral...


Nov 07, 2017, 16:01 ET Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the third quarter ended September 30,...


Oct 24, 2017, 17:00 ET Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2017 on Tuesday, November 7,...


Oct 10, 2017, 18:15 ET Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit...


Oct 02, 2017, 09:15 ET Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch

Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic...


Sep 29, 2017, 13:00 ET Vanda to Present Scientific Posters at World Sleep 2017

Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced participation at the 2017 joint congress of World Association of Sleep Medicine...


Sep 13, 2017, 16:04 ET Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced results from an 8-week randomized Phase II clinical study of tradipitant as a...


Sep 11, 2017, 17:00 ET Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in...


Sep 06, 2017, 17:00 ET Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the Citi 12th Annual Biotech Conference. Vanda will...


Aug 02, 2017, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the second quarter ended June 30,...


Jul 21, 2017, 07:00 ET Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the European Medicines Agency's Committee for Medicinal Product for Human...